CS0159 compared with placebo for primary biliary cholangitis when UDCA is not enough

Trial details

Who runs it

Cascade Pharmaceuticals, Inc

Trial code

NCT07282353

Record updated

8 July 2026

Original description

A Randomized, Double-Blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of CS0159 in Patients with Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid (UDCA).Read full original descriptionShow less

A Randomized, Double-Blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of CS0159 in Patients With Primary Biliary Cholangitis (PBC) With Inadequate Response or Intolerance to Ursodeoxycholic Acid (UDCA)

A Randomized, Double-Blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of CS0159 in Patients with Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid (UDCA).

Inclusion: Must have given written informed consent (signed and dated) and any authorizations required by local law; When signing ICF age ≥18 years ≤75 years, male or female; Meets the diagnostic criteria of PBC, based on any two of the following criteria:; History of ALP above 1.0× ULN for at least 6 months; Positive antimitochondrial antibody (AMA) titer (>1:40 on immunofluorescence or M2 positive by ELISA) or positive PBC- specific antinuclear antibody (ANA) (either SP100 or GP210 positive); Documented liver biopsy results consistent with PBC; UDCA≥6 months before randomization and a stable dose ≥3 months after the efficacy was poor [meeting inclusion criteria (5)a], or UDCA was not tolerated, and stop taking UDCA (no UDCA use for ≥3 months before randomization); Laboratory parameters measured at screening period meet the following criteria:; ALP ≥1.67× ULN; ALT≤5× ULN; AST ≤5× ULN; TB <2× ULN; Estimated glomerular filtration rate (eGFR) > 60mL/min/1.73m2 (calculated by CKD-EPI equation); Platelet count ≥ 1.0× LLN (No thrombocytopenia-related treatment within the past two weeks); Albumin> 35g/L; White blood cells count (WBC) >3×109/L; Absolute neutrophil count (ANC) >1.5×109/L; Hemoglobin A1c (HbA1c) ≤9.0%; INR ≤ 1.0× ULN. For participants on anticoagulation therapy, INR must be maintained in the range required for prophylaxis for their specific disease; Females of reproductive potential must use at least 1 barrier contraceptive and a second effective birth control method during the study and for at least 90 days after the last dose. Male participants who are sexually active with female partners of reproductive potential must use barrier contraception, and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose; -.

Exclusion: Previous exposure to CS0159; Other concomitant liver disease including:; Autoimmune hepatitis (AIH) (simplified AIH diagnostic score >6), PBC-AIH overlap syndrome, or overlap with other autoimmune liver diseases; Positive HBsAg or positive HCV RNA (tested for in case of known cured HCV infection or positive HCV Ab at screening); Primary sclerosing cholangitis (PSC); History or clinical evidence of Alcoholic liver disease (ALD); Biopsy confirmed Non-alcoholic steatohepatitis (NASH); Gilbert's Syndrome; History or evidence of alpha-1 antitrypsin deficiency; Liver stiffness measured by transient elastography (TE) > 16.9 Kpa; History or presence of any disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs including bile salt metabolism in the large intestine, eg, inflammatory bowel disease, prior or planned (during the study period) bariatric surgery (such as gastroplasty, roux-en-Y gastric bypass); Drug abuse or heavy alcohol use from 12 months prior to randomization throughout the entire clinical study period. Heavy alcohol use is defined as an average weekly alcohol consumption of more than approximately 7 standard drinks for females and more than approximately 14 standard drinks for males. One standard drink is defined as any beverage containing 14g of pure alcohol, such as 12 oz/360 mL of beer (5% alcohol), 8 oz/240 mL of malt liquor (7% alcohol), 5 oz/150 mL of wine (12% alcohol), or 1.5 oz/45 mL of distilled spirits (40% alcohol); Treatment with any other investigational therapy or device within 30 days or within 5 half-lives, whichever is longer, prior to screening; History of allergy to the CS0159 or its excipients or drugs of similar chemical classes; Patient has a positive test for HIV at screening, or active syphilis [defined as positive Treponema pallidum antibody (TP Ab) and a rapid plasma reagin (RPR) card test titer ≥1:8; for low titers (e.g., 1:1 or 1:2), clinical judgment is required to determine if it is active syphilis]; Medical conditions that may cause non-hepatic increases in ALP (e.g., paget's disease); Any other condition(s) that would compromise the safety of the patient or compromise the quality of the clinical study, as judged by the investigator; -; Advanced PBC as defined by the Rotterdam criteria (albumin<1.0×LLN AND TB >1.0× ULN); Patients who have had clinically significant complications of hepatic cirrhosis with clinically significant portal hypertension (CSPH), including the following:; History of liver transplantation, current placement on a liver transplant list, current MELD -Na score ≥ 12; History of confirmed esophagogastric variceal bleeding; Clinically significant ascites requiring intervention, such as sodium restriction, diuretic therapy, or therapeutic paracentesis; Any secondary complications resulting from clinically significant ascites, such as spontaneous bacterial peritonitis, hepatorenal syndrome, or hepatic hydrothorax; Hepatic encephalopathy requiring drug therapy; Portopulmonary hypertension and/or hepatopulmonary syndrome; Hepatocellular carcinoma; Administration of the following medications are prohibited as specified below:; Use of medications, food, and drinks (e.g., grapefruit juice) that are strong or moderate CYP3A4 inhibitors or inducers within 14 days before randomization; Use of P-glycoprotein (P-gp) substrate drugs within 14 days before randomization; 2 months prior to randomization: fibrates, glitazones, seladelpar and elafibranor; 3 months prior to randomization: obeticholic acid (OCA), azathioprine, colchicine, cyclosporine, methotrexate, mycophenolate, pentoxifylline, systemic corticosteroids and budesonide (˃2 weeks); potentially hepatotoxic drugs (including α-methyl-dopa, sodium valproic acid isoniazid, or nitrofurantoin); Patients with systemic treatment for pruritus (e.g., with bile acid sequestrants [BAS]) within 3 months prior to randomization; 12 months prior to randomization: antibodies or immunotherapy directed against ILs or other cytokines or chemokines; Patients with severe arrhythmia, or a QTcF interval corrected by Fridericia's formula ≥450 ms (males) or ≥470 ms (females) at screening [Fridericia's formula: QTcF=QT/(RR\^0.33)]; History of malignancy (except for those with a disease-free survival of ≥5 years) or currently under evaluation for malignancy. Except for cases with long-term stable disease and assessed by the investigator as having no significant impact on the trial-such as cured squamous or non-invasive basal cell skin carcinoma, cervical carcinoma in situ, mild to moderate cervical dysplasia, or incidental prostate cancer stage T1a; Poor blood pressure control is indicated after treatment by a systolic pressure greater than 160 mmHg or diastolic pressure greater than 100 mmHg during screening; Pregnancy, planned pregnancy, lactation; Mental instability or incompetence that may compromise the validity of informed consent or ability to adhere to study requirements.

ClinicalTrials.gov NCT07282353